NASDAQ:ESPR - Esperion Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$42.14 -0.64 (-1.50 %)
(As of 05/20/2018 05:45 AM ET)
Previous Close$42.14
Today's Range$41.15 - $42.99
52-Week Range$30.95 - $82.68
Volume751,777 shs
Average Volume2.44 million shs
Market Capitalization$1.13 billion
P/E Ratio-6.04
Dividend YieldN/A
Beta2.52

About Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics logoEsperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Receive ESPR News and Ratings via Email

Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ESPR
CUSIPN/A
Phone734-887-3903

Debt

Debt-to-Equity RatioN/A
Current Ratio6.70
Quick Ratio6.70

Price-To-Earnings

Trailing P/E Ratio-6.04
Forward P/E Ratio-7.02
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.99 per share
Price / Book5.27

Profitability

EPS (Most Recent Fiscal Year)($6.98)
Net Income$-166,980,000.00
Net MarginsN/A
Return on Equity-77.47%
Return on Assets-67.65%

Miscellaneous

Employees57
Outstanding Shares26,790,000

Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics (NASDAQ:ESPR) released its quarterly earnings results on Wednesday, May, 2nd. The biopharmaceutical company reported ($1.73) EPS for the quarter, missing the Zacks' consensus estimate of ($1.56) by $0.17. During the same period in the prior year, the business earned ($1.80) earnings per share. View Esperion Therapeutics' Earnings History.

When is Esperion Therapeutics' next earnings date?

Esperion Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Esperion Therapeutics.

What price target have analysts set for ESPR?

13 equities research analysts have issued 1-year target prices for Esperion Therapeutics' stock. Their predictions range from $41.00 to $153.00. On average, they anticipate Esperion Therapeutics' share price to reach $89.0769 in the next year. View Analyst Ratings for Esperion Therapeutics.

What are Wall Street analysts saying about Esperion Therapeutics stock?

Here are some recent quotes from research analysts about Esperion Therapeutics stock:
  • 1. Chardan Capital analysts commented, "We see numerous reasons for our new positive bias, including: A path forward for both BA and a BA+ezetimibe (BA+eze) fixed dose combo (FDC) has been confirmed by the FDA. A definition of statin intolerance has also been agreed on by the FDA. KOLs (e.g. Dr. Nissen) support the need for therapies for patients who are (or believe themselves to be) statin intolerant and refuse statins. CANTOS suggests BA’s high-sensitivity C-reactive protein (hsCRP) lowering effect is highly relevant for CV event reduction and outcomes. Newly-disclosed integrated phase II results suggest sound BA safety. A larger market opportunity results from a pivotal BA phase III design that includes patients “on any statin dose.” Limited use of PCSK9 inhibitors, due to pricing, opens an opportunity. Merck’s (unrated) decision not to file anacetrapib for approval further confirms oral CETP inhibitors as uninteresting assets or competitors." (12/5/2017)
  • 2. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (8/23/2017)

Who are some of Esperion Therapeutics' key competitors?

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the folowing people:
  • Mr. Timothy M. Mayleben, CEO, Pres & Director (Age 57)
  • Dr. Narendra D. Lalwani Ph.D., FAHA, DABT, MBA, Chief Operating Officer and Exec. VP of R&D (Age 65)
  • Dr. Mary P. McGowan M.D., Chief Medical Officer (Age 58)
  • Mr. Richard B. Bartram, CFO, Principal Accounting Officer & Corp. Sec.
  • Ms. Marianne Andreach, Sr. VP of Product Planning

Has Esperion Therapeutics been receiving favorable news coverage?

Media headlines about ESPR stock have been trending somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Esperion Therapeutics earned a coverage optimism score of 0.13 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.93 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BB Biotech AG (9.01%), BlackRock Inc. (5.56%), Pinnacle Associates Ltd. (2.36%), Wasatch Advisors Inc. (2.21%), Northern Trust Corp (2.16%) and Amundi Pioneer Asset Management Inc. (1.10%). Company insiders that own Esperion Therapeutics stock include Dov A Md Goldstein, Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani, Nicole Vitullo and Roger S Newton. View Institutional Ownership Trends for Esperion Therapeutics.

Which major investors are selling Esperion Therapeutics stock?

ESPR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Lord Abbett & CO. LLC, Wasatch Advisors Inc., Candriam Luxembourg S.C.A., New York State Common Retirement Fund, Pinnacle Associates Ltd., BlackRock Inc. and Guggenheim Capital LLC. Company insiders that have sold Esperion Therapeutics company stock in the last year include Nicole Vitullo and Roger S Newton. View Insider Buying and Selling for Esperion Therapeutics.

Which major investors are buying Esperion Therapeutics stock?

ESPR stock was bought by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Bellevue Group AG, JPMorgan Chase & Co., SG Americas Securities LLC, Amundi Pioneer Asset Management Inc., A.R.T. Advisors LLC, BB Biotech AG and Spark Investment Management LLC. Company insiders that have bought Esperion Therapeutics stock in the last two years include Gilbert S Omenn, Mark E Mcgovern and Narendra D Lalwani. View Insider Buying and Selling for Esperion Therapeutics.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $42.14.

How big of a company is Esperion Therapeutics?

Esperion Therapeutics has a market capitalization of $1.13 billion. The biopharmaceutical company earns $-166,980,000.00 in net income (profit) each year or ($6.98) on an earnings per share basis. Esperion Therapeutics employs 57 workers across the globe.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]


MarketBeat Community Rating for Esperion Therapeutics (ESPR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  370 (Vote Outperform)
Underperform Votes:  298 (Vote Underperform)
Total Votes:  668
MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe ESPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESPR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Esperion Therapeutics (NASDAQ:ESPR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
13 Wall Street analysts have issued ratings and price targets for Esperion Therapeutics in the last 12 months. Their average twelve-month price target is $89.0769, suggesting that the stock has a possible upside of 111.38%. The high price target for ESPR is $153.00 and the low price target for ESPR is $41.00. There are currently 2 sell ratings, 2 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.622.772.772.67
Ratings Breakdown: 2 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $89.0769$96.3077$77.2308$58.9167
Price Target Upside: 111.38% upside28.96% upside0.04% upside21.40% upside

Esperion Therapeutics (NASDAQ:ESPR) Consensus Price Target History

Price Target History for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2018UBSSet Price TargetBuy$90.00 ➝ $75.00LowView Rating Details
5/4/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$108.00 ➝ $73.00N/AView Rating Details
5/3/2018JPMorgan ChaseDowngradeNeutral ➝ Underweight$100.54 ➝ $41.00HighView Rating Details
5/3/2018Deutsche BankLower Price TargetBuy ➝ Buy$100.00 ➝ $75.00HighView Rating Details
5/2/2018Bank of AmericaReiterated RatingBuy ➝ UnderperformHighView Rating Details
4/19/2018Northland SecuritiesBoost Price TargetBuy$100.00 ➝ $121.00LowView Rating Details
3/27/2018Chardan CapitalBoost Price TargetNeutral ➝ Neutral$75.00 ➝ $100.00LowView Rating Details
3/8/2018JMP SecuritiesBoost Price TargetOutperform$60.00 ➝ $153.00HighView Rating Details
3/7/2018Stifel NicolausSet Price TargetBuy$105.00HighView Rating Details
2/21/2018Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$81.00 ➝ $94.00LowView Rating Details
1/22/2018CitigroupDowngradeBuy ➝ Neutral$77.00 ➝ $96.00LowView Rating Details
9/7/2017CowenInitiated CoverageOutperform$64.00LowView Rating Details
8/21/2017Jefferies GroupReiterated RatingBuy$85.00LowView Rating Details
3/20/2017Royal Bank of CanadaReiterated RatingHold$45.00HighView Rating Details
8/31/2016BarclaysSet Price TargetHold$13.00N/AView Rating Details
7/5/2016WallachBeth CapitalDowngradeBuy ➝ Hold$35.00N/AView Rating Details
6/29/2016Lake Street CapitalLower Price TargetBuy$80.00 ➝ $27.00N/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Esperion Therapeutics (NASDAQ:ESPR) Earnings History and Estimates Chart

Earnings by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR) Earnings Estimates

2018 EPS Consensus Estimate: ($6.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.42)($1.42)($1.42)
Q2 20181($1.92)($1.92)($1.92)
Q3 20181($1.37)($1.37)($1.37)
Q4 20181($1.39)($1.39)($1.39)

Esperion Therapeutics (NASDAQ ESPR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($1.62)N/AView Earnings Details
5/2/2018Q1 2018($1.56)($1.73)ViewN/AView Earnings Details
2/20/2018Q4 2017($1.80)($1.44)ViewN/AView Earnings Details
11/7/2017Q3 2017($1.79)($1.86)ViewN/AView Earnings Details
8/8/2017Q2 2017($1.67)($1.92)ViewListenView Earnings Details
5/1/2017Q1 2017($1.4410)($1.80)ViewN/AView Earnings Details
2/22/201712/31/2016($1.24)($1.29)ViewN/AView Earnings Details
11/3/2016Q3($0.82)($0.77)ViewN/AView Earnings Details
8/4/2016Q2($0.78)($0.62)ViewN/AView Earnings Details
5/4/2016Q116($0.74)($0.65)ViewN/AView Earnings Details
2/25/2016Q4($0.6050)($0.58)ViewN/AView Earnings Details
11/5/2015Q3($0.60)($0.57)ViewN/AView Earnings Details
8/6/2015Q215($0.58)($0.55)ViewN/AView Earnings Details
5/7/2015Q115($0.54)($0.56)ViewN/AView Earnings Details
3/5/2015Q4 2014($0.54)($0.49)ViewN/AView Earnings Details
11/10/2014Q3 2014($0.68)($0.64)ViewN/AView Earnings Details
8/12/2014Q214($0.55)($0.60)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.62)($0.51)ViewN/AView Earnings Details
3/5/2014($0.50)($0.63)ViewN/AView Earnings Details
11/6/2013Q3 2013($0.41)($0.34)ViewN/AView Earnings Details
8/12/2013Q2 2013($12.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Esperion Therapeutics (NASDAQ:ESPR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Esperion Therapeutics (NASDAQ ESPR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 32.50%
Institutional Ownership Percentage: 91.38%
Insider Trading History for Esperion Therapeutics (NASDAQ:ESPR)
Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ ESPR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/29/2018Roger S NewtonDirectorSell25,000$72.37$1,809,250.00639,682View SEC Filing  
1/25/2018Nicole VitulloDirectorSell11,674$71.79$838,076.463,177View SEC Filing  
12/6/2017Nicole VitulloDirectorSell9,326$53.85$502,205.102,472View SEC Filing  
3/22/2017Dov A Md GoldsteinDirectorSell800,000$41.66$33,328,000.00View SEC Filing  
3/21/2017Gilbert S OmennDirectorBuy1,000$42.26$42,260.0010,000View SEC Filing  
11/1/2016Narendra D LalwaniCOOBuy5,000$9.93$49,650.005,000View SEC Filing  
7/6/2016Mark E McgovernDirectorBuy5,000$10.00$50,000.00600View SEC Filing  
5/4/2016Timothy M MaylebenCEOBuy7,000$14.85$103,950.0041,614View SEC Filing  
3/1/2016Gilbert S OmennDirectorBuy5,000$15.28$76,400.0010,000View SEC Filing  
1/27/2016Timothy M MaylebenCEOBuy3,600$15.88$57,168.0034,614View SEC Filing  
1/15/2016Timothy M MaylebenCEOBuy7,200$14.08$101,376.0031,014View SEC Filing  
4/24/2015Dov A Md GoldsteinDirectorSell217,469$108.22$23,534,495.18View SEC Filing  
11/18/2014Patrick G EnrightDirectorSell487,130$32.78$15,968,121.40View SEC Filing  
10/21/2014Parters Vii L P DomainMajor ShareholderBuy500,000$20.00$10,000,000.00View SEC Filing  
10/7/2014Longitude Capital Partners, LlMajor ShareholderSell11,927$30.04$358,287.08View SEC Filing  
7/1/2013Brian H DoveyMajor ShareholderBuy285,714$14.00$3,999,996.00View SEC Filing  
7/1/2013Daniel JanneyDirectorBuy235,714$14.00$3,299,996.00View SEC Filing  
7/1/2013Roger S NewtonChairmanBuy42,346$14.00$592,844.00View SEC Filing  
7/1/2013Timothy M MaylebenCEOBuy5,000$14.00$70,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Esperion Therapeutics (NASDAQ ESPR) News Headlines

Source:
DateHeadline
Esperion Therapeutics (ESPR) Expected to Post Earnings of -$1.76 Per ShareEsperion Therapeutics (ESPR) Expected to Post Earnings of -$1.76 Per Share
www.americanbankingnews.com - May 19 at 1:23 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – ESPRSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – ESPR
finance.yahoo.com - May 19 at 8:37 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018
finance.yahoo.com - May 17 at 5:41 PM
ESPR REMINDER: Pawar Law Reminds Investors of Important July 6, 2018 Lead Plaintiff Deadline in Class Action– ESPRESPR REMINDER: Pawar Law Reminds Investors of Important July 6, 2018 Lead Plaintiff Deadline in Class Action– ESPR
finance.yahoo.com - May 17 at 5:41 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018 – ESPRSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018 – ESPR
feeds.benzinga.com - May 16 at 7:27 PM
ESPR ALERT: Rosen Law Firm Reminds Esperion Therapeutics, Inc. Investors of Important July 6 Deadline in Class ActionESPR ALERT: Rosen Law Firm Reminds Esperion Therapeutics, Inc. Investors of Important July 6 Deadline in Class Action
www.bizjournals.com - May 16 at 5:11 PM
Esperion Therapeutics (ESPR) Presents At Bank Of America Merrill Lynch 2018 Healthcare Conference - SlideshowEsperion Therapeutics (ESPR) Presents At Bank Of America Merrill Lynch 2018 Healthcare Conference - Slideshow
seekingalpha.com - May 16 at 5:11 PM
Esperion Therapeutics (ESPR) Buy Rating Reiterated at UBSEsperion Therapeutics' (ESPR) Buy Rating Reiterated at UBS
www.americanbankingnews.com - May 16 at 1:49 PM
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmIMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - May 16 at 8:54 AM
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Esperion Therapeutics, Inc. (ESPR)The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Esperion Therapeutics, Inc. (ESPR)
finance.yahoo.com - May 15 at 5:27 PM
DEADLINE ALERT: Shareholder Class Action Lawsuit Filed Against Esperion Therapeutics, Inc. – ESPRDEADLINE ALERT: Shareholder Class Action Lawsuit Filed Against Esperion Therapeutics, Inc. – ESPR
finance.yahoo.com - May 15 at 9:01 AM
Buyer of Esperion Therapeutics (ESPR) on Weakness - Needham & CompanyBuyer of Esperion Therapeutics (ESPR) on Weakness - Needham & Company
www.streetinsider.com - May 14 at 5:03 PM
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Esperion Therapeutics, Inc. (ESPR)The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Esperion Therapeutics, Inc. (ESPR)
finance.yahoo.com - May 14 at 5:03 PM
ESPR INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible ...ESPR INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible ...
www.businesswire.com - May 12 at 9:05 AM
INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmINVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - May 12 at 9:04 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ESPRSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ESPR
finance.yahoo.com - May 12 at 9:04 AM
Esperion Therapeutics (ESPR) Presents At 43rd Annual Deutsche Bank Healthcare Conference - SlideshowEsperion Therapeutics (ESPR) Presents At 43rd Annual Deutsche Bank Healthcare Conference - Slideshow
seekingalpha.com - May 10 at 5:26 PM
ESPR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of ...ESPR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of ...
www.businesswire.com - May 10 at 5:26 PM
Important Deadline Notice for Esperion Therapeutics, Inc. Shareholders - ESPRImportant Deadline Notice for Esperion Therapeutics, Inc. Shareholders - ESPR
finance.yahoo.com - May 10 at 5:26 PM
ESPR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Esperion Therapeutics, Inc.ESPR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Esperion Therapeutics, Inc.
finance.yahoo.com - May 10 at 5:26 PM
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics, Inc.Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics, Inc.
finance.yahoo.com - May 10 at 5:26 PM
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Esperion Therapeutics, Inc. - ESPRSHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Esperion Therapeutics, Inc. - ESPR
finance.yahoo.com - May 10 at 5:26 PM
Kessler Topaz Meltzer & Check, LLP Announces Investor Class Action Filed Against Esperion Therapeutics, Inc. - ESPRKessler Topaz Meltzer & Check, LLP Announces Investor Class Action Filed Against Esperion Therapeutics, Inc. - ESPR
finance.yahoo.com - May 10 at 5:26 PM
Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2018 Healthcare ConferenceEsperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2018 Healthcare Conference
globenewswire.com - May 10 at 8:52 AM
Pomerantz Law Firm Announces the Filing of a Class Action against Esperion Therapeutics, Inc. and Certain Officers – ESPRPomerantz Law Firm Announces the Filing of a Class Action against Esperion Therapeutics, Inc. and Certain Officers – ESPR
globenewswire.com - May 9 at 5:09 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Esperion Therapeutics, Inc.INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Esperion Therapeutics, Inc.
finance.yahoo.com - May 9 at 5:09 PM
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmSHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - May 9 at 5:09 PM
Deadline Alert for Esperion Therapeutics, Inc. Shareholders in Class Action Lawsuit - ESPRDeadline Alert for Esperion Therapeutics, Inc. Shareholders in Class Action Lawsuit - ESPR
finance.yahoo.com - May 9 at 8:48 AM
ESPERION INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Esperion Therapeutics, Inc. To Contact The FirmESPERION INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Esperion Therapeutics, Inc. To Contact The Firm
finance.yahoo.com - May 9 at 8:48 AM
EQUITY ALERT: Rosen Law Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics, Inc ...EQUITY ALERT: Rosen Law Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics, Inc ...
www.businesswire.com - May 8 at 5:11 PM
Pomerantz Law Firm Announces the Filing of a Class Action against Esperion Therapeutics, Inc. and Certain Officers ...Pomerantz Law Firm Announces the Filing of a Class Action against Esperion Therapeutics, Inc. and Certain Officers ...
www.globenewswire.com - May 8 at 5:11 PM
Bragar Eagel & Squire, PC Announces That a Class Action Lawsuit Has Been Filed Against Esperion Therapeutics, Inc ...Bragar Eagel & Squire, PC Announces That a Class Action Lawsuit Has Been Filed Against Esperion Therapeutics, Inc ...
www.businesswire.com - May 8 at 5:11 PM
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Esperion Therapeutics, Inc. (ESPR) and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Esperion Therapeutics, Inc. (ESPR) and Encourages Investors to Contact the Firm
finance.yahoo.com - May 8 at 5:11 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Esperion Therapeutics, Inc.SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Esperion Therapeutics, Inc.
finance.yahoo.com - May 8 at 5:11 PM
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmIMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - May 8 at 5:11 PM
Is Esperion Therapeutics Inc. a Buy on the Dip?Is Esperion Therapeutics Inc. a Buy on the Dip?
finance.yahoo.com - May 8 at 8:44 AM
Esperion Therapeutics (ESPR) Receives Consensus Rating of "Buy" from AnalystsEsperion Therapeutics (ESPR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 7 at 3:37 PM
Q2 2018 EPS Estimates for Esperion Therapeutics (ESPR) Lowered by Jefferies GroupQ2 2018 EPS Estimates for Esperion Therapeutics (ESPR) Lowered by Jefferies Group
www.americanbankingnews.com - May 7 at 2:26 AM
JPMorgan Downgrades Esperion Therapeutics (ESPR) to Underweight Citing an Extended Road to RecoveryJPMorgan Downgrades Esperion Therapeutics (ESPR) to Underweight Citing an Extended Road to Recovery
www.streetinsider.com - May 5 at 5:11 PM
Analyzing the Research Pipeline of Esperion TherapeuticsAnalyzing the Research Pipeline of Esperion Therapeutics
finance.yahoo.com - May 5 at 8:54 AM
Analyzing the Financial Performance of Esperion TherapeuticsAnalyzing the Financial Performance of Esperion Therapeutics
finance.yahoo.com - May 5 at 8:54 AM
Esperion Therapeutics (ESPR) PT Lowered to $73.00Esperion Therapeutics (ESPR) PT Lowered to $73.00
www.americanbankingnews.com - May 5 at 2:59 AM
Here's Why Esperion Therapeutics Inc. Stock Is Bouncing Back TodayHere's Why Esperion Therapeutics Inc. Stock Is Bouncing Back Today
finance.yahoo.com - May 4 at 5:05 PM
Esperion to Participate in Fireside Chat at the Deutsche Bank 43rd Annual Health Care ConferenceEsperion to Participate in Fireside Chat at the Deutsche Bank 43rd Annual Health Care Conference
finance.yahoo.com - May 4 at 5:05 PM
Heres Why Esperion Therapeutics Inc. Stock Is Bouncing Back TodayHere's Why Esperion Therapeutics Inc. Stock Is Bouncing Back Today
www.fool.com - May 4 at 1:17 PM
Esperion Therapeutics Target of Unusually Large Options Trading (ESPR)Esperion Therapeutics Target of Unusually Large Options Trading (ESPR)
www.americanbankingnews.com - May 4 at 8:21 AM
Esperion Therapeutics (ESPR) Rating Increased to Strong-Buy at ValuEngineEsperion Therapeutics (ESPR) Rating Increased to Strong-Buy at ValuEngine
www.americanbankingnews.com - May 3 at 10:05 PM
Analysts Defend Esperion As Shares Sell Off SharplyAnalysts Defend Esperion As Shares Sell Off Sharply
www.msn.com - May 3 at 5:02 PM
Important Stock Score Report Updates for Esperion Therapeutics, Integrated Media Technology, Mastercard, Molson Coors, and WayfairImportant Stock Score Report Updates for Esperion Therapeutics, Integrated Media Technology, Mastercard, Molson Coors, and Wayfair
www.bizjournals.com - May 3 at 5:02 PM
Esperion Therapeutics (ESPR) Rating Reiterated by Deutsche BankEsperion Therapeutics (ESPR) Rating Reiterated by Deutsche Bank
www.americanbankingnews.com - May 3 at 4:31 PM

SEC Filings

Esperion Therapeutics (NASDAQ:ESPR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Esperion Therapeutics (NASDAQ:ESPR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Esperion Therapeutics (NASDAQ ESPR) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.